143 related articles for article (PubMed ID: 37875480)
21. Therapeutic targeting of BET bromodomain protein, Brd4, delays cyst growth in ADPKD.
Zhou X; Fan LX; Peters DJ; Trudel M; Bradner JE; Li X
Hum Mol Genet; 2015 Jul; 24(14):3982-93. PubMed ID: 25877301
[TBL] [Abstract][Full Text] [Related]
22. Inhibition of nucleophosmin 1 suppresses colorectal cancer tumor growth of patient -derived xenografts via activation of p53 and inhibition of AKT.
Yu ACY; Chern YJ; Zhang P; Pasiliao CC; Rahman M; Chang G; Ren J; Tai IT
Cancer Biol Ther; 2021 Feb; 22(2):112-123. PubMed ID: 33446037
[TBL] [Abstract][Full Text] [Related]
23. CUL4B/miR-33b/C-MYC axis promotes prostate cancer progression.
Zhao M; Qi M; Li X; Hu J; Zhang J; Jiao M; Bai X; Peng X; Han B
Prostate; 2019 Apr; 79(5):480-488. PubMed ID: 30609075
[TBL] [Abstract][Full Text] [Related]
24. Nucleophosmin promotes lung adenocarcinoma cell proliferation, migration and invasion by activating the EGFR/MAPK signaling pathway.
Li M; Wu R; Zhu D; Wang L; Liu S; Wang R; Deng C; Zhang S; Chen M; Lu R; Zhu H; Mo M; Luo Z
Oncol Rep; 2023 Jun; 49(6):. PubMed ID: 37165929
[TBL] [Abstract][Full Text] [Related]
25. JQ1 and PI3K inhibition synergistically reduce salivary adenoid cystic carcinoma malignancy by targeting the c-Myc and EGFR signaling pathways.
Liu X; Wu H; Huang P; Zhang F
J Oral Pathol Med; 2019 Jan; 48(1):43-51. PubMed ID: 30269363
[TBL] [Abstract][Full Text] [Related]
26. Targeting bromodomain-containing protein 4 (BRD4) inhibits MYC expression in colorectal cancer cells.
Otto C; Schmidt S; Kastner C; Denk S; Kettler J; Müller N; Germer CT; Wolf E; Gallant P; Wiegering A
Neoplasia; 2019 Nov; 21(11):1110-1120. PubMed ID: 31734632
[TBL] [Abstract][Full Text] [Related]
27. Validation of Bromodomain and Extraterminal proteins as therapeutic targets in neurofibromatosis type 2.
Doherty J; Mandati V; González Rodriguez MA; Troutman S; Shepard A; Harbaugh D; Brody R; Miller DC; Kareta MS; Kissil JL
Neurooncol Adv; 2022; 4(1):vdac072. PubMed ID: 35855490
[TBL] [Abstract][Full Text] [Related]
28. BRD4 promotes gastric cancer progression through the transcriptional and epigenetic regulation of c-MYC.
Ba M; Long H; Yan Z; Wang S; Wu Y; Tu Y; Gong Y; Cui S
J Cell Biochem; 2018 Jan; 119(1):973-982. PubMed ID: 28681984
[TBL] [Abstract][Full Text] [Related]
29. Bromodomain Protein BRD4-Mediated Mutant p53 Transcription Promotes TNBC Progression.
Zhou JX; Agborbesong E; Li LX; Li X
Int J Mol Sci; 2022 Dec; 23(23):. PubMed ID: 36499487
[No Abstract] [Full Text] [Related]
30. BET bromodomain inhibition targets both c-Myc and IL7R in high-risk acute lymphoblastic leukemia.
Ott CJ; Kopp N; Bird L; Paranal RM; Qi J; Bowman T; Rodig SJ; Kung AL; Bradner JE; Weinstock DM
Blood; 2012 Oct; 120(14):2843-52. PubMed ID: 22904298
[TBL] [Abstract][Full Text] [Related]
31. A novel dual epigenetic approach targeting BET proteins and HDACs in Group 3 (MYC-driven) Medulloblastoma.
Kling MJ; Kesherwani V; Mishra NK; Alexander G; McIntyre EM; Ray S; Challagundla KB; Joshi SS; Coulter DW; Chaturvedi NK
J Exp Clin Cancer Res; 2022 Nov; 41(1):321. PubMed ID: 36357906
[TBL] [Abstract][Full Text] [Related]
32. BET bromodomain protein inhibition is a therapeutic option for medulloblastoma.
Henssen A; Thor T; Odersky A; Heukamp L; El-Hindy N; Beckers A; Speleman F; Althoff K; Schäfers S; Schramm A; Sure U; Fleischhack G; Eggert A; Schulte JH
Oncotarget; 2013 Nov; 4(11):2080-95. PubMed ID: 24231268
[TBL] [Abstract][Full Text] [Related]
33. BET Bromodomain Blockade Mitigates Intimal Hyperplasia in Rat Carotid Arteries.
Wang B; Zhang M; Takayama T; Shi X; Roenneburg DA; Kent KC; Guo LW
EBioMedicine; 2015 Nov; 2(11):1650-61. PubMed ID: 26870791
[TBL] [Abstract][Full Text] [Related]
34. Targeting MYC activity in double-hit lymphoma with MYC and BCL2 and/or BCL6 rearrangements with epigenetic bromodomain inhibitors.
Li W; Gupta SK; Han W; Kundson RA; Nelson S; Knutson D; Greipp PT; Elsawa SF; Sotomayor EM; Gupta M
J Hematol Oncol; 2019 Jul; 12(1):73. PubMed ID: 31288832
[TBL] [Abstract][Full Text] [Related]
35. Co-overexpression of BRD4 and CDK7 promotes cell proliferation and predicts poor prognosis in HCC.
Li X; Zheng C; Liu Y; Sun H; Qian Y; Fan H
Heliyon; 2024 Jan; 10(2):e24389. PubMed ID: 38293462
[TBL] [Abstract][Full Text] [Related]
36. KDM5C is transcriptionally regulated by BRD4 and promotes castration-resistance prostate cancer cell proliferation by repressing PTEN.
Hong Z; Wu G; Xiang ZD; Xu CD; Huang SS; Li C; Shi L; Wu DL
Biomed Pharmacother; 2019 Jun; 114():108793. PubMed ID: 30921702
[TBL] [Abstract][Full Text] [Related]
37. Targeting Hippo coactivator YAP1 through BET bromodomain inhibition in esophageal adenocarcinoma.
Song S; Li Y; Xu Y; Ma L; Pool Pizzi M; Jin J; Scott AW; Huo L; Wang Y; Lee JH; Bhutani MS; Weston B; Shanbhag ND; Johnson RL; Ajani JA
Mol Oncol; 2020 Jun; 14(6):1410-1426. PubMed ID: 32175692
[TBL] [Abstract][Full Text] [Related]
38. Oncogene c-fos and mutant R175H p53 regulate expression of Nucleophosmin implicating cancer manifestation.
Senapati P; Dey S; Sudarshan D; Das S; Kumar M; Kaypee S; Mohiyuddin A; Kodaganur GS; Kundu TK
FEBS J; 2018 Sep; 285(18):3503-3524. PubMed ID: 30085406
[TBL] [Abstract][Full Text] [Related]
39. High expression of NPM1 via the Wnt/β-catenin signalling pathway might predict poor prognosis for patients with prostate adenocarcinoma.
Ruan Y; Xu H; Ji X
Clin Exp Pharmacol Physiol; 2022 Apr; 49(4):525-535. PubMed ID: 35108408
[TBL] [Abstract][Full Text] [Related]
40. circNR3C1 Suppresses Bladder Cancer Progression through Acting as an Endogenous Blocker of BRD4/C-myc Complex.
Xie F; Xiao X; Tao D; Huang C; Wang L; Liu F; Zhang H; Niu H; Jiang G
Mol Ther Nucleic Acids; 2020 Dec; 22():510-519. PubMed ID: 33230453
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
